BACKGROUND: Increasing numbers of women in resource-rich settings are prescribed zidovudine (ZDV)-sparing highly active antiretroviral therapy (HAART) in pregnancy. We compare ZDV-sparing with ZDV-containing HAART in relation to maternal viral load at delivery, mother-to-child transmission (MTCT) of HIV, and congenital abnormality. METHODS: This is an analysis of data from the National Study of HIV in Pregnancy and Childhood and the European Collaborative Study. Data on 7573 singleton births to diagnosed HIV-infected women between January 2000 and June 2009 were analyzed. Logistic regression models were fitted to estimate adjusted odds ratios (AORs). RESULTS: Overall, 15.8% (1199 of 7573) of women received ZDV-sparing HAART, with increasing use between 2000 and 2009 (P < 0.001). Nearly a fifth (18.4%) of women receiving ZDV-sparing HAART in pregnancy had a detectable viral load at delivery compared with 28.6% of women on ZDV-containing HAART [AOR 0.90; 95% confidence interval (CI): 0.72 to 1.14, P = 0.4]. MTCT rates were 0.8% and 0.9% in the ZDV-sparing and ZDV-containing groups, respectively (AOR 1.81; 95% CI: 0.77 to 4.26, P = 0.2). The congenital abnormality rate was the same in both groups (2.7%, AOR 0.98; 95% CI: 0.66 to 1.45, P = 0.9), with no significant difference between the groups in a subanalysis of pregnancies with first trimester HAART exposure (AOR 0.79; 95% CI: 0.48 to 1.30, P = 0.4). CONCLUSIONS: We found no difference in risk of detectable viral load at delivery, MTCT, or congenital abnormality when comparing ZDV-sparing with ZDV-containing HAART. With increasing use of ZDV-sparing HAART, continued monitoring of pregnancy outcomes and long-term consequences of in utero exposure to these drugs is required.
BACKGROUND: Increasing numbers of women in resource-rich settings are prescribed zidovudine (ZDV)-sparing highly active antiretroviral therapy (HAART) in pregnancy. We compare ZDV-sparing with ZDV-containing HAART in relation to maternal viral load at delivery, mother-to-child transmission (MTCT) of HIV, and congenital abnormality. METHODS: This is an analysis of data from the National Study of HIV in Pregnancy and Childhood and the European Collaborative Study. Data on 7573 singleton births to diagnosed HIV-infected women between January 2000 and June 2009 were analyzed. Logistic regression models were fitted to estimate adjusted odds ratios (AORs). RESULTS: Overall, 15.8% (1199 of 7573) of women received ZDV-sparing HAART, with increasing use between 2000 and 2009 (P < 0.001). Nearly a fifth (18.4%) of women receiving ZDV-sparing HAART in pregnancy had a detectable viral load at delivery compared with 28.6% of women on ZDV-containing HAART [AOR 0.90; 95% confidence interval (CI): 0.72 to 1.14, P = 0.4]. MTCT rates were 0.8% and 0.9% in the ZDV-sparing and ZDV-containing groups, respectively (AOR 1.81; 95% CI: 0.77 to 4.26, P = 0.2). The congenital abnormality rate was the same in both groups (2.7%, AOR 0.98; 95% CI: 0.66 to 1.45, P = 0.9), with no significant difference between the groups in a subanalysis of pregnancies with first trimester HAART exposure (AOR 0.79; 95% CI: 0.48 to 1.30, P = 0.4). CONCLUSIONS: We found no difference in risk of detectable viral load at delivery, MTCT, or congenital abnormality when comparing ZDV-sparing with ZDV-containing HAART. With increasing use of ZDV-sparing HAART, continued monitoring of pregnancy outcomes and long-term consequences of in utero exposure to these drugs is required.
Authors: B G Gazzard; Jane Anderson; Abdel Babiker; Marta Boffito; Gary Brook; Gary Brough; Duncan Churchill; Ben Cromarty; Satyajit Das; Martin Fisher; Andrew Freedman; Anna Maria Geretti; Margaret Johnson; Saye Khoo; Clifford Leen; Devaki Nair; Barry Peters; Andrew Phillips; Deenan Pillay; Anton Pozniak; John Walsh; Ed Wilkins; Ian Williams; Matthew Williams; Mike Youle Journal: HIV Med Date: 2008-10 Impact factor: 3.180
Authors: S Blanche; M Tardieu; P Rustin; A Slama; B Barret; G Firtion; N Ciraru-Vigneron; C Lacroix; C Rouzioux; L Mandelbrot; I Desguerre; A Rötig; M J Mayaux; J F Delfraissy Journal: Lancet Date: 1999-09-25 Impact factor: 79.321
Authors: Koen K A Van Rompay; Laurie L Brignolo; Dennis J Meyer; Christopher Jerome; Ross Tarara; Abigail Spinner; Marta Hamilton; Linda L Hirst; David R Bennett; Don R Canfield; Trish G Dearman; Wilhelm Von Morgenland; Phil C Allen; Celia Valverde; Alesha B Castillo; R Bruce Martin; Valerie F Samii; Ray Bendele; John Desjardins; Marta L Marthas; Niels C Pedersen; Norbert Bischofberger Journal: Antimicrob Agents Chemother Date: 2004-05 Impact factor: 5.191
Authors: E M Connor; R S Sperling; R Gelber; P Kiselev; G Scott; M J O'Sullivan; R VanDyke; M Bey; W Shearer; R L Jacobson Journal: N Engl J Med Date: 1994-11-03 Impact factor: 91.245
Authors: A de Ruiter; D Mercey; J Anderson; R Chakraborty; P Clayden; G Foster; C Gilling-Smith; D Hawkins; N Low-Beer; H Lyall; S O'Shea; Z Penn; J Short; R Smith; S Sonecha; P Tookey; C Wood; G Taylor Journal: HIV Med Date: 2008-08 Impact factor: 3.180
Authors: Claire L Townsend; Barbara A Willey; Mario Cortina-Borja; Catherine S Peckham; Pat A Tookey Journal: AIDS Date: 2009-02-20 Impact factor: 4.177
Authors: Kathryn Rough; Jenny W Sun; George R Seage; Paige L Williams; Krista F Huybrechts; Brian T Bateman; Sonia Hernandez-Diaz Journal: AIDS Date: 2017-07-31 Impact factor: 4.177
Authors: Susie E Huntington; Loveleen K Bansi; Claire Thorne; Jane Anderson; Marie-Louise Newell; Graham P Taylor; Deenan Pillay; Teresa Hill; Pat A Tookey; Caroline A Sabin Journal: BMC Med Res Methodol Date: 2012-07-28 Impact factor: 4.615
Authors: Osvaldo Lorenzo; Consuelo M Beck-Sagué; Claudia Bautista-Soriano; Mina Halpern; José Roman-Poueriet; Nora Henderson; Eddy Perez-Then; Rosa Abreu-Perez; Solange Soto; Luis Martínez; Sarah Rives-Gray; Bienvenido Veras; Maureen Connolly; Greer Brittany Callender; Stephen W Nicholas Journal: Infect Dis Obstet Gynecol Date: 2012-11-29